MS Prevention Trial update
the PrevANZ vitamin D MS prevention trial, supported by the Trish Multiple
Sclerosis Research Foundation, are well underway with recruitment expected to
commence in October 2012.
experienced MS clinical trial sites in all states of Australia and in New
Zealand, have come on board to participate in the trial.
finalisation of the protocol, submissions for ethics approvals and site
initiation are underway and respected not-for-profit contract research
organisation, Neuroscience Trials Australia has been recruited to assist with
logistical aspects of the trial.
One of the most
highly respected MS radiology teams, led by Prof David Miller at University
College London, UK, have also come on board to provide their expertise in the
central reading of the MRI scans that will be used to monitor patients in the
patients into the trial will occur through neurologists over a three year
period, with final results expected in 2016. Eligible patients will be those
who, at the time of enrolment, have recently experienced their very first
episode of symptoms suggestive of MS – this is termed a first demyelinating
event, or clinically isolated syndrome. Typically, 70-80% of these patients
would go on to experience a second episode and receive a diagnosis of
clinically definite MS. The trial will test whether vitamin D supplementation
can prevent the development of MS in these patients.
MSRA CEO, Mr
Jeremy Wright, said, ‘We have an extremely experienced team running this trial
and we have every confidence that it will provide a clear answer on the optimum
dosage and the benefits that can be expected from vitamin D for MS prevention.’
sufficient funding to include nearly 200 patients (cases) and make this a
statistically powerful trial. With further funding we can recruit the full
cohort of 240 patients needed to provide the most accurate data possible.’
People with MS who
are concerned about their vitamin D levels should seek advice from their GP or